Clinical Trial Update: Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating the combination of sintilimab and chidamide for peripheral T-cell lymphoma, with recruitment ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Chidamide (chidamide)
• Sintilimab (sintilimab)

Snippet

Sponsor: Fudan University | Conditions: Peripheral T-cell Lymphoma | Phase 2 | Status: RECRUITING